<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01602250</url>
  </required_header>
  <id_info>
    <org_study_id>P100501</org_study_id>
    <nct_id>NCT01602250</nct_id>
  </id_info>
  <brief_title>Local Anaesthetics Toxicity and Intralipid®</brief_title>
  <acronym>TOXALIP</acronym>
  <official_title>Prevention of Systemic Toxicity Induced by Levobupivacaine and Ropivacaine by Intralipid®</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The systemic toxicity of local anaesthetics may be treated using lipid emulsions (&quot;lipid
      rescue&quot;). However, there is no evidence-based proof of the efficacy of the treatment. The aim
      of the intended protocol is to study the effect of the emulsion Intralipid® on the toxicity
      prodromes in volunteers receiving either levobupivacaine or ropivacaine. After a
      sensitization session with lidocaine, subjects will receive in a double blind, crossover
      manner an i.v. infusion of levobupivacaine or ropivacaine followed by a rapid infusion of
      Intralipid®. The primary outcome will be the time of appearance of early neurologic signs of
      toxicity. In addition, the EEG and ECG will be monitored and blood sampling will be performed
      in order to evaluate the changes in pharmacokinetics induced by the emulsion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Regional anaesthesia may induce toxic neurologic and cardiac reactions related to inadvertent
      intravenous injection or rapid absorption of local anaesthetics. Despite the appearance of
      the less toxic agents ropivacaine and levobupivacaine, the problem remains. Recently, a new
      therapeutics called &quot;lipid rescue&quot; emerged. This rapid injection of a lipid emulsion is
      supposed to act as a lipid sink, thus delaying the release of the toxic molecules to the
      target organs. Animal studies as well as clinical reports seem to favour this treatment.
      However, there is no evidence-based proof of the efficacy of this &quot;lipid rescue&quot;.

      The aim of the study is 1) to verify the efficacy of a lipid emulsion (Intralipid® 20%) on
      the toxicity induced by the local anaesthetics ropivacaine and levobupivacaine and 2) to
      compare the effect of the emulsion on the two agents.

      Sixteen volunteers with strictly normal ECG and EEG will participate to the study.

      After a sensitization session with lidocaine, the subjects will receive levobupivacaine or
      ropivacaine i.v. at a rate of 8 mg/min (max 120 mg) followed two minutes after the beginning
      of infusion by a bolus injection of Intralipid® 20% or of saline 120 mL in 1 minute. The
      infusion of local anaesthetics will be stopped immediately at the appearance of the early
      signs of toxicity. In addition to the recognition of the signs by the subject (trained by the
      sensitization session), an anaesthesiologist will ask if the subject has any symptom. A
      continuous monitoring of the EEG and of the ECG will be performed.

      Sixteen subjects completing the study have been considered necessary to achieve a power of 90
      % with an alpha risk of 5 %. A mean time to first signs of 3.8 ± 1.2 min has been considered
      in the placebo groups. A 45 % difference in the primary outcome has been considered. The
      study will be double blind crossover as a Latin square (four treatments, four sessions, four
      replications).

      The investigators will consider the time between infusion initiation and appearance of the
      early signs of toxicity as primary outcome. The secondary outcomes will be the changes in ECG
      and EEG variables and the pharmacokinetic parameters observed. For that purpose, blood will
      be sampled until the 8th hour after the beginning of local anaesthetic infusion.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of drug infusion</measure>
    <time_frame>less than 15 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>EEG : electroencephalogram</measure>
    <time_frame>&lt; 15 minutes</time_frame>
    <description>Detection of sub-clinical seizure activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG : electrocardiogram</measure>
    <time_frame>&lt; 15 minutes</time_frame>
    <description>Duration of PR, QRs intervals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pharmacokinetics of local anesthetics (Area under the plasma concentration versus time curve (AUC))</measure>
    <time_frame>8 h</time_frame>
    <description>blood concentration of local anesthetics during 8 hours post administration : Area under the plasma concentration versus time curve (AUC)&quot;</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Toxicity</condition>
  <condition>Adverse Effects</condition>
  <arm_group>
    <arm_group_label>levobupivacaine placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>levobupivacaine placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>levobupivacaine Intralipid®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>levobupivacaine Intralipid®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ropivacaine Intralipid®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ropivacaine Intralipid®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ropivacaine placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>ropivacaine placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Levobupivacaine 8 mg/min ropivacaine 8 mg/min</description>
    <arm_group_label>levobupivacaine placebo</arm_group_label>
    <arm_group_label>ropivacaine placebo</arm_group_label>
    <other_name>levobupivacaine</other_name>
    <other_name>ropivacaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intralipid®</intervention_name>
    <description>Levobupivacaine 8 mg/min ropivacaine 8 mg/min Intralipid® 120 ml in one min</description>
    <arm_group_label>levobupivacaine Intralipid®</arm_group_label>
    <arm_group_label>ropivacaine Intralipid®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Volunteers ASA1

        Exclusion Criteria:

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dan Benhamou</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CIC plurithématique Paris-Est (CIC-9304)</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Dureau P, Charbit B, Nicolas N, Benhamou D, Mazoit JX. Effect of Intralipid® on the Dose of Ropivacaine or Levobupivacaine Tolerated by Volunteers: A Clinical and Pharmacokinetic Study. Anesthesiology. 2016 Sep;125(3):474-83. doi: 10.1097/ALN.0000000000001230.</citation>
    <PMID>27404223</PMID>
  </results_reference>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2012</study_first_submitted>
  <study_first_submitted_qc>May 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2012</study_first_posted>
  <last_update_submitted>December 20, 2016</last_update_submitted>
  <last_update_submitted_qc>December 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anesthetics, local</keyword>
  <keyword>Toxicity</keyword>
  <keyword>Adverse effects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
    <mesh_term>Levobupivacaine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Soybean oil, phospholipid emulsion</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

